No Data
No Data
List of Unrivaled Stocks (Part 2) [Ichimoku Equilibrium Chart/Kumoku Stock List]
○List of Unbroken Stocks Market Code Stock Name Closing Price Advance Span A Advance Span B Tokyo Stock Exchange Prime <1786> Oriental Shiraishi 376 391.25 378 <1871> PS Mitsubishi 992 1054 1004 <1925> Daiwa House 4407 4411 4460.5 <1946> Toe
Cloud Stock List (Weekly) (Part 1)
○Kumojo Stock List Market Code Stock Name Closing Price Advance Span A Advance Span B Tokyo Stock Exchange Prime <1375> Yukiguni Maitake 984 928.75 969.5 <1515> Nittetsu Mining 4825 4783.75 4283 <1762> Takamatsu G 2620 2616 2377 <1808>
Convertible Stock List (Part 1) [Parabolic Signal Convertible Stock List]
○List of purchase-conversion stocks market code stock name closing price SAR Tokyo Stock Exchange Prime <1766> Token Corpo 10670 10130 <1884> day road 1874 1773 <1925> Daiwa House 4283 4172 <1964 > Chugai furnace 2884 2710 <2060> feed one
BB Tower, etc. [A strange brand seen from changes in turnover]
Stock closing price turnover compared to the previous day*<2342>trans G 263 38 1513600*<3776>BB tower 179 5 15758900*<3891>high paper 2052 141 308200*<9417>smabaru 472 80 270300*<6962>large vacuum 817 34 1107000*<9932>Sugimoto Shoji
Brands that moved the day before part 1 Japan Aviation Electronics Industry, CUC, Metawater, etc.
<コード>Stock name closing price on the 25th ⇒ Hulic <3003> 1424.5 -63.5 1st quarter operating profit decreased 30.5% compared to the previous day. Marubeni Leasing <9763> 3065 +10924 financial results and dividend forecasts for the fiscal year ending March 31, 24 were revised upward. Ishizuka Nitro <5204> operating profit for the fiscal year ending 2682 -16525 is expected to decrease 54.2%. Daiichi Sankyo <4568> 4766 +37 share buying/cancellation with an upper limit of 2.87% of the number of issued shares. Business is growing but stock prices are sluggish. No. 1<
Meta Water, Canon, Avionics, etc.
<4519> Chugai Pharmaceutical 4860-291 continued to decline drastically. Financial results for the first quarter were announced the day before. Core operating income was 102.1 billion yen, down 3.1% from the same period last year, but market consensus has improved due to a cost ratio decline higher than expected. However, sales revenue declined drastically, with a 24.1% decrease from the same period. In addition to the decline in sales due to the completion of deliveries to the Rona Grove government, Babysmo, Alesensa, etc. also fell short of expectations, and overseas shipments of Actemra also seem to have declined due to the effects of biosimilars. sluggish
No Data